Objective To assess the performance of the 2023 ACR/EULAR classification criteria (2023
AECC) for antiphospholipid syndrome (APS) in a Mexican cohort. Methods We enrolled …

Objective To systematically review the efficacy and safety data of different therapeutic
approaches in patients with antiphospholipid antibodies (aPL) and thrombosis. Methods The …

Objectives To explore the clinical and serological course of fertile women with positive
antiphospholipid (aPL), and the factors and therapeutic implications associated with aPL …

The description of antiphospholipid syndrome (APS) is vascular thrombosis and/or
pregnancy morbidity occurring in persons with antiphospholipid antibodies (aPL). However …

Objective Antiphospholipid antibodies (aPL), namely anticardiolipin antibodies (aCL) and
lupus anticoagulant (LAC), have been associated with an increased risk of thrombosis in …

Objectives: To asses risk factors for a first thrombotic event in antiphospholipid antibody
(aPL) positive carriers and evaluate the efficacy of prophylactic treatments. Methods …

Objective. Most clinicians use the 2006 Sydney classification criteria to evaluate patients
suspected of having antiphospholipid syndrome (APS). Although sensitive and specific for …

Antiphospholipid syndrome (APS) is a thromboinflammatory syndrome characterized by
thrombotic, microvascular, obstetric, or non-thrombotic events in the setting of persistent …

Objective It has been suggested that only antibodies against domain 1 (D1) of β2‐
glycoprotein I (β2GPI) are pathogenic and diagnostic. The role of antibodies against other …

The presence of antiphospholipid antibodies (aPL) combined with venous or arterial
thrombosis, and/or obstetric complications defines the antiphospholipid syndrome (APS) …